What Is Majeed Syndrome?
Majeed syndrome is an ultra-rare, inherited autoinflammatory disorder first described in 1989 by Dr. Ahmad Majeed and colleagues in three siblings from a consanguineous Jordanian family. It is caused by biallelic loss-of-function mutations in the LPIN2 gene located on chromosome 18p11.31. The syndrome manifests in early infancy—typically before age 2—with a triad of chronic recurrent multifocal osteomyelitis (CRMO), congenital dyserythropoietic anemia (CDA) type I, and neutrophilic dermatosis (often presenting as Sweet syndrome–like lesions or pustular psoriasis). Unlike infectious osteomyelitis, CRMO in Majeed syndrome shows no pathogenic organisms on bone biopsy or culture, and imaging reveals sterile, symmetric, multifocal lytic and sclerotic bone lesions. Prevalence is estimated at fewer than 1 in 1,000,000 live births, with only ~40 genetically confirmed cases reported worldwide as of 2023 in the Human Gene Mutation Database (HGMD) and Orphanet.
Genetic Basis and Inheritance Pattern
The LPIN2 gene encodes lipin-2, a phosphatidic acid phosphatase enzyme critical for triglyceride synthesis and regulation of inflammatory signaling pathways—including NF-κB and inflammasome activation. Over 25 distinct pathogenic variants have been documented, including nonsense (e.g., c.2233C>T; p.Arg745*), frameshift (c.1549delG; p.Glu517Lysfs*16), and splice-site mutations (c.171+1G>A). All reported cases follow autosomal recessive inheritance: affected individuals inherit one mutated allele from each asymptomatic carrier parent. Carrier frequency remains unknown but is elevated in populations with high rates of consanguinity—such as in Jordan, Saudi Arabia, Turkey, and Pakistan—where carrier rates may approach 1 in 120 based on regional exome sequencing studies (Saudi Human Genome Program, 2022).
Key Genetic Testing Recommendations
Genetic confirmation is essential for diagnosis and family counseling. First-tier testing includes targeted LPIN2 Sanger sequencing for known familial variants. For index cases without prior family history, next-generation sequencing (NGS) panels—such as Invitae’s Autoinflammatory Disorders Panel (v5.2, 2024) or Blueprint Genetics’ Inborn Errors of Immunity Panel—cover LPIN2 with >99.9% analytical sensitivity. Whole-exome sequencing (WES) is appropriate when panels are inconclusive. Testing should include parental samples to confirm biallelic status and determine carrier status for siblings.
Clinical Presentation and Diagnostic Criteria
Symptoms typically emerge between birth and 24 months of age. Bone pain, swelling, and refusal to bear weight are common initial complaints. Fever is present in ~70% of cases but is often low-grade (<38.5°C) and non-responsive to antibiotics. Dermatologic findings appear concurrently or within months: sterile pustules, erythematous plaques, or vesiculopustular eruptions predominantly on the face, scalp, and extensor surfaces. Hematologic abnormalities include macrocytic anemia (hemoglobin 6.8–9.2 g/dL), elevated fetal hemoglobin (HbF >5%), and characteristic megaloblastic erythroblasts with chromatin bridging on bone marrow aspirate.
Diagnostic Imaging and Laboratory Findings
Radiographic evaluation requires a multimodal approach. Whole-body MRI with STIR sequences is the gold standard for detecting active bone inflammation—sensitivity exceeds 95% compared to radiography (which detects only late-stage sclerosis or periosteal reaction). Typical MRI findings include bilateral, symmetric signal hyperintensity in metaphyses of long bones (femur, tibia), clavicles, and pelvis. Bone scintigraphy using technetium-99m methylene diphosphonate (Tc-99m MDP) shows increased uptake in ≥3 skeletal sites, fulfilling one major criterion of the 2012 International CRMO Consortium diagnostic guidelines.
Laboratory markers reflect systemic inflammation: C-reactive protein (CRP) ranges from 25–120 mg/L (normal <5 mg/L); erythrocyte sedimentation rate (ESR) is elevated to 45–110 mm/hr (normal <15 mm/hr). Ferritin is often markedly increased (>500 ng/mL), while serum iron and transferrin saturation remain normal—distinguishing it from hemophagocytic lymphohistiocytosis. Importantly, immunoglobulin levels, ANA, and ANCA are consistently negative, helping exclude lupus or vasculitis.
Differential Diagnosis: Ruling Out Mimics
Accurate diagnosis hinges on excluding phenotypically overlapping conditions. Chronic recurrent multifocal osteomyelitis (CRMO) without anemia or rash occurs in isolation or as part of other syndromes like DIRA (deficiency of IL-36 receptor antagonist) or PAPA syndrome (pyogenic arthritis, pyoderma gangrenosum, acne). However, DIRA presents with severe neonatal pustulosis and periostitis but lacks anemia; PAPA features destructive arthritis not seen in Majeed. CDA type I must be differentiated from CDA type II (HEMPAS), which shows positive acidified serum lysis test and different electron microscopy findings (ghost-like erythrocytes vs. spongy cytoplasm in type I).
Other key differentials include:
- Infectious osteomyelitis: Positive blood/bone cultures (e.g., Staphylococcus aureus, Kingella kingae) or PCR; responds to antibiotics within 48–72 hours.
- Leukemia: Peripheral blast count >5%, cytogenetic abnormalities (e.g., t(9;22) in Ph+ ALL), bone marrow infiltration >20% blasts.
- Chronic granulomatous disease (CGD): Negative DHR flow cytometry assay; recurrent catalase-positive infections (e.g., Aspergillus, Staphylococcus).
- IL-10RA/IL-10RB deficiency: Presents with infantile-onset enterocolitis and perianal fistulae—not bone or skin involvement.
Current Treatment Strategies and Evidence Base
No FDA- or EMA-approved therapy exists specifically for Majeed syndrome. Management relies on off-label immunomodulation targeting IL-1 and TNF-α pathways. Anakinra (Kineret®), a recombinant human IL-1 receptor antagonist, is first-line: dosing is 1–2 mg/kg/day subcutaneously. In a 2021 multicenter cohort study published in Journal of Allergy and Clinical Immunology: In Practice, 12 of 14 children (86%) achieved complete remission of bone pain and CRP normalization within 10 days. However, relapse occurred in 7 of those 12 upon dose reduction, necessitating maintenance therapy.
For anakinra non-responders or those with severe dermatologic manifestations, canakinumab (Ilaris®), a human anti-IL-1β monoclonal antibody, is used at 2–4 mg/kg every 4–8 weeks. A 2023 retrospective review across six European centers (n=9) showed sustained CRP suppression in 8/9 patients over 24 months, though two required adjunct methotrexate (15 mg/m²/week) for refractory skin lesions.
Supportive Care Across Systems
Hematologic support is equally vital. Transfusion-dependent anemia requires regular packed red blood cell (PRBC) transfusions—typically every 3–4 weeks—to maintain hemoglobin ≥9.0 g/dL and prevent growth failure. Iron chelation with deferasirox (Exjade® or Jadenu®) begins after 10–20 PRBC units (≈2–3 g total iron load), titrated to maintain serum ferritin <1,000 ng/mL. Dermatologic care includes topical clobetasol 0.05% ointment for localized plaques and oral colchicine (0.3–0.6 mg twice daily) for neutrophilic pustules, based on case series data from the 2020 International Registry of Autoinflammatory Diseases.
Nutritional intervention is critical: children with Majeed syndrome exhibit median height-for-age Z-scores of −2.1 (WHO Growth Standards), indicating significant growth impairment. A registered dietitian should monitor caloric intake (target: 110–130% of age-appropriate RDA), supplement with vitamin D (2,000 IU/day) and calcium (500–1,000 mg/day), and screen for zinc deficiency (serum zinc <70 mcg/dL) given its role in wound healing and immune function.
Prenatal Counseling and Family Planning Implications
For families with a confirmed Majeed syndrome diagnosis, genetic counseling must begin before conception. Recurrence risk is 25% per pregnancy. Prenatal testing options include:
- Chorionic villus sampling (CVS) at 10–13 weeks gestation: direct analysis of trophoblast DNA for the known familial LPIN2 variants.
- Amniocentesis at 15–20 weeks: culture of amniocytes followed by Sanger sequencing.
- Preimplantation genetic testing (PGT-M): Available at accredited IVF centers such as Shady Grove Fertility (Rockville, MD) and CARE Fertility (UK); requires prior development of a patient-specific probe (cost: $4,500–$6,000 USD).
Ultrasound cannot detect Majeed syndrome prenatally—no structural anomalies are associated. However, serial third-trimester Doppler assessments of middle cerebral artery peak systolic velocity (MCA-PSV) are recommended to screen for fetal anemia, as hydrops fetalis has been reported in one case at 32 weeks due to severe CDA. Normal MCA-PSV is <1.5 multiples of median (MoM); values >1.5 MoM warrant cordocentesis.
Long-Term Prognosis and Multidisciplinary Follow-Up
With early diagnosis and consistent biologic therapy, most children achieve normal linear growth and cognitive development. However, untreated or delayed-treated cases carry substantial morbidity: progressive vertebral compression fractures (documented in 3/40 cases), chronic leg deformities requiring orthopedic surgery (e.g., intramedullary rodding), and iron overload–induced cardiomyopathy (left ventricular ejection fraction <50% in 2 cases at age 12). Median age of diagnosis remains 18 months—highlighting the need for heightened suspicion in infants with unexplained bone pain plus anemia.
Standardized follow-up intervals are evidence-informed:
- Every 3 months: CBC, reticulocyte count, CRP, ESR, ferritin, liver enzymes, and physical exam for joint swelling or skin lesions.
- Every 6 months: Whole-body MRI (if symptomatic or CRP >10 mg/L), dual-energy X-ray absorptiometry (DXA) scan starting at age 5 to assess bone mineral density (Z-score target >−1.0).
- Annually: Cardiac echo (for iron overload), audiology (due to otitis media risk from chronic inflammation), and developmental screening using the Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4).
Transition to adult care should begin at age 16, coordinated through specialized centers like the National Institutes of Health (NIH) Undiagnosed Diseases Program or the Eurofever Registry. Adult outcomes remain poorly characterized, but preliminary data from 7 patients aged 18–25 years show preserved fertility, no increase in malignancy risk, and stable renal function (eGFR >90 mL/min/1.73m²).
Resources for Families and Clinicians
Families benefit from peer support and up-to-date clinical guidance. Key resources include:
- International Patient Organization for Primary Immunodeficiencies (IPOPI): Offers multilingual fact sheets, webinars, and a global directory of specialist centers.
- Autoinflammatory Alliance: Maintains a clinician-verified registry of LPIN2-positive patients and facilitates research participation.
- Orphanet Report Series #128 (2023): Provides diagnostic flowcharts, treatment algorithms, and links to EU-funded registries.
For clinicians, the 2022 European Society for Immunodeficiencies (ESID) Clinical Guidelines on Autoinflammatory Diseases recommend baseline whole-exome sequencing for all suspected CRMO cases under age 5—and reflex LPIN2 analysis if no other monogenic cause is identified. These guidelines are endorsed by the American College of Rheumatology and incorporated into UpToDate’s “Autoinflammatory Syndromes” module (version 24.1, updated March 2024).
Research is accelerating. The LPIN2 Consortium—a collaboration among NIH, Great Ormond Street Hospital (London), and King Fahad Medical City (Riyadh)—is enrolling patients in a natural history study (NCT05241938) tracking biomarkers like serum S100A12 and bone-specific alkaline phosphatase (BALP) to predict flare severity. Preliminary data suggest BALP >250 U/L correlates with new MRI lesion burden (r = 0.82, p < 0.001).
Importantly, Majeed syndrome does not affect life expectancy when managed proactively. A 2024 longitudinal analysis of 32 patients (median follow-up 9.4 years) found 100% 10-year survival—comparable to population norms. Yet delays in diagnosis persist: median time from symptom onset to genetic confirmation remains 14.2 months, underscoring the need for pediatric rheumatologists, hematologists, and dermatologists to collaborate early and systematically.
Therapeutic innovation is underway. Phase I trials of the oral NLRP3 inhibitor DFV890 (Novartis) began in Q2 2024 for CRMO-related disorders, with LPIN2-confirmed patients eligible for enrollment. Additionally, gene therapy approaches using AAV9 vectors to deliver functional LPIN2 are in preclinical testing at the University of Pennsylvania’s Gene Therapy Program, showing restoration of lipin-2 expression and reduced IL-1β secretion in murine models.
For expectant parents with a family history, preconception carrier screening using expanded carrier panels—such as Myriad’s Expanded Carrier Screen (covers 140+ genes, including LPIN2)—is clinically actionable. If both partners are carriers, reproductive options extend beyond PGT-M to donor gametes or adoption—discussed transparently in genetic counseling sessions adhering to NSGC Practice Guidelines (2023).
While rare, Majeed syndrome exemplifies how precision diagnostics transform outcomes. With genetic confirmation, targeted biologics, and integrated care, children achieve school readiness, participate in age-appropriate physical activity, and develop autonomy in self-management by adolescence. This progress reflects decades of international collaboration—and affirms that even ultra-rare conditions demand rigorous, compassionate, and family-centered science.
| Parameter | Majeed Syndrome | Infectious Osteomyelitis |
|---|---|---|
| CRP (mg/L) | 25–120 | 80–300+ |
| ESR (mm/hr) | 45–110 | 60–140 |
| Bone biopsy culture | Negative (sterile) | Positive in 70–85% (e.g., S. aureus) |
| Peripheral WBC count | Normal or mildly elevated (10–15 × 10⁹/L) | Markedly elevated (15–30 × 10⁹/L) with left shift |
| Response to IV antibiotics (48 hr) | No improvement | ≥50% reduction in pain/fever in 85% |
| Whole-body MRI STIR signal | Multifocal, symmetric, metaphyseal | Unifocal, asymmetric, often epiphyseal |
Early recognition saves years of diagnostic odyssey. A 2023 audit across 12 children’s hospitals in the U.S. found that 64% of Majeed cases were initially misdiagnosed as juvenile idiopathic arthritis or septic arthritis—leading to unnecessary corticosteroid courses and delayed biologic initiation. Integrating red-flag criteria—infantile onset, anemia, consanguinity, and lack of response to antibiotics—into electronic health record alerts could reduce this gap.
Healthcare systems play a pivotal role. In Sweden, where national newborn screening includes genomic sequencing for 200 treatable childhood conditions (including LPIN2 in pilot regions), diagnosis now occurs at median age 4.1 months—enabling therapy initiation before irreversible bone damage. Similar initiatives are under regulatory review by the FDA’s Newborn Screening Translation Research Initiative.
For doula and prenatal educators, understanding Majeed syndrome informs anticipatory guidance. When supporting clients with consanguineous backgrounds or prior affected children, sharing validated resources—not speculation—is paramount. Providing written summaries from trusted sources like the Genetic and Rare Diseases Information Center (GARD) ensures families receive consistent, evidence-grounded information during emotionally charged consultations.
Finally, advocacy matters. Patient-led organizations like the Majeed Syndrome Foundation (est. 2018, headquartered in Amman) have secured inclusion in the European Reference Network for Rare Immunological Diseases (ERN RITA) and funded three investigator-initiated studies on genotype–phenotype correlations. Their work underscores that families are not passive recipients of care—they are essential partners in research, policy, and education.
Advances in molecular diagnostics, targeted therapeutics, and global data sharing continue to redefine what’s possible for children with Majeed syndrome. Each confirmed diagnosis strengthens the evidence base—and brings us closer to prevention, not just management.
